Literature DB >> 10357843

Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred.

L Haddad1, I N Day, S Hunt, R R Williams, S E Humphries, P N Hopkins.   

Abstract

Monogenically inherited hypercholesterolemia is most commonly caused by mutations at the low density lipoprotein receptor (LDLR) locus causing familial hypercholesterolemia (FH) or at the apolipoprotein B (APOB) locus causing the disorder familial defective apoB (FDB). Probands from 47 kindreds with a strict clinical diagnosis of FH were selected from the Cardiovascular Genetics Research Lipid Clinic, Utah, for molecular genetic analysis. Using a combination of single-strand conformation polymorphism (SSCP) and direct sequencing, 12 different LDLR gene mutations were found in 16 of the probands. Three of the probands were carriers of the APOB R3500Q mutation. In five of the remaining 28 pedigrees where no mutation had been detected, samples from enough relatives were available to examine co-segregation with the LDLR region using the microsatellite marker D19S221, which is within 1 Mb centromeric of the LDLR locus, and D19S394, sited within 150 kb telomeric of the LDLR locus. In four of the families there was strong evidence for co-segregation between the LDLR locus and the phenotype of hypercholesterolemia, but in one large family with 18 living affected members and clear-cut bimodal hypercholesterolemia, there were numerous exclusions of co-segregation. Using length polymorphic markers within and outside the APOB gene, linkage of phenotype in this family to the APOB region was similarly excluded. In this large family, the degree of hypercholesterolemia, prevalence of tendon xanthomata, and occurrence of early coronary disease were indistinguishable from the other families studied. In summary, the data provide unequivocal evidence that a third locus can be etiological for monogenic familial hypercholesterolemia and should be reinvigorating to research in this field.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10357843

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  14 in total

Review 1.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

Review 2.  Science, medicine, and the future: Genetics and cardiovascular risk.

Authors:  I N Day; D I Wilson
Journal:  BMJ       Date:  2001-12-15

Review 3.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

Authors:  Daniel J Rader; Jonathan Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

4.  Human genetics as a foundation for innovative drug development.

Authors:  Alexander Kamb; Sean Harper; Kari Stefansson
Journal:  Nat Biotechnol       Date:  2013-11       Impact factor: 54.908

5.  Predominance of a 6 bp deletion in exon 2 of the LDL receptor gene in Africans with familial hypercholesterolaemia.

Authors:  R Thiart; C L Scholtz; J Vergotine; C F Hoogendijk; J N de Villiers; H Nissen; K Brusgaard; D Gaffney; M S Hoffs; W J Vermaak; M J Kotze
Journal:  J Med Genet       Date:  2000-07       Impact factor: 6.318

6.  Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia.

Authors:  D Norman; X M Sun; M Bourbon; B L Knight; R P Naoumova; A K Soutar
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

7.  Use of homozygosity mapping to identify a region on chromosome 1 bearing a defective gene that causes autosomal recessive homozygous hypercholesterolemia in two unrelated families.

Authors:  E R Eden; R P Naoumova; J J Burden; M I McCarthy; A K Soutar
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

8.  Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene.

Authors:  Mariame El Messal; Karima Aït Chihab; Rachid Chater; Joan Carles Vallvé; Faïza Bennis; Aïcha Hafidi; Josep Ribalta; Mathilde Varret; Mohammed Loutfi; Jean Pierre Rabès; Anass Kettani; Catherine Boileau; Luis Masana; Ahmed Adlouni
Journal:  J Hum Genet       Date:  2003-03-18       Impact factor: 3.172

9.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

Review 10.  Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia.

Authors:  Piotr Pęczek; Mateusz Leśniewski; Tomasz Mazurek; Lukasz Szarpak; Krzysztof J Filipiak; Aleksandra Gąsecka
Journal:  Life (Basel)       Date:  2021-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.